{
    "clinical_study": {
        "@rank": "67163", 
        "arm_group": [
            {
                "arm_group_label": "Biolimus A9 eluting stent", 
                "arm_group_type": "Experimental", 
                "description": "biolimus A9 stent( Biomatrix or Biomatrix Flex) will be placed in  under Percutaneous Transluminal Coronary Angioplasty"
            }, 
            {
                "arm_group_label": "Zotarolimus-eluting stent", 
                "arm_group_type": "Active Comparator", 
                "description": "zotarolimus eluting stent (Resolute Integrity) will be placed in under Percutaneous Transluminal Coronary Angioplasty"
            }
        ], 
        "brief_summary": {
            "textblock": "The risk of restenosis in the treatment of coronary artery disease has significantly\n      lessened thanks to the introduction of Drug eluting stent.\n\n      Yet, debates on the efficacy and safety of stents in complex lesions or patients have been\n      circulated.\n\n      Recently, PCI in multiple lesions is universally performed with the development of effective\n      stents in various kinds in the clinics.\n\n      However, a randomized study  is rare for  multi-vessel coronary artery disease in real\n      procedural environments.\n\n      The primary purpose of this study is to evaluate the clinical progress of biolimus\n      A9-eluting stent and zotarolimus-eluting stent in multi-vessel coronary artery disease."
        }, 
        "brief_title": "Comparison of the Biolimus A9-eluting Stent With the Zotarolimus -Eluting Stent in Multi-vessel PCI", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Multivessel Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "The patients who need multi-vessel stenting with multi-vessel coronary artery disease will\n      be enrolled.Each randomization of the enrolled subjects will be done 1:1 (biolimus\n      A9-eluting stent : zotarolimus-eluting stent). Randomization will be stratified by two\n      factors: Diabetes mellitus and Acute coronary syndrome.Clinical follow-up will occur at the\n      following time points; 1 month, 1 year and 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients who need multi-vessel stenting with multi-vessel disease\n\n          -  patients with signed informed consent\n\n        Exclusion Criteria:\n\n          -  known contraindication to any of the following medications: Aspirin,clopidogrel,\n             heparin, contrast agent, Biolimus or Zotarolimus group\n\n          -  Cardiogenic shock\n\n          -  Patients with primary PCI\n\n          -  Pregnant women or women with potential childbearing\n\n          -  End-stage diseases with life expectancy shorter than 2 years\n\n          -  patients with other Drug eluting stents implanted\n\n          -  Patients requiring modification of antiplatelet agents for planned major surgery\n             within the first 12 months after the enrollment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "840", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01947439", 
            "org_study_id": "BATTLE IN MULTI"
        }, 
        "intervention": {
            "arm_group_label": [
                "Biolimus A9 eluting stent", 
                "Zotarolimus-eluting stent"
            ], 
            "description": "Percutaneous Transluminal coronary angioplasty will be performed in both of randomized groups of  biolimus A9 eluting stent and zotarolimus eluting stent", 
            "intervention_name": "Percutaneous Transluminal Coronary Angioplasty", 
            "intervention_type": "Device", 
            "other_name": [
                "-Resolute Integrity", 
                "-Biomatrix", 
                "-Biomatrix Flex"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "multivessel stenting", 
        "lastchanged_date": "September 23, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Yeungnam University Hospital"
                }, 
                "investigator": {
                    "last_name": "Woong Kim", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Daegu Catholic University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Jin-Bae Lee", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Daegu Fatima Hospital"
                }, 
                "investigator": {
                    "last_name": "Bong-Ryeol Lee", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "KyungPook National University Hospital"
                }, 
                "investigator": {
                    "last_name": "Jang-Hoon Lee", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 4, Prospective,Multicenter Study of Randomized Comparison of the Biolimus A9-eluting Stent With the Zotarolimus-eluting Stent in Multi-vessel PCI", 
        "overall_contact": {
            "email": "namcwcv@gmail.com", 
            "last_name": "Chang-Wook Nam, Postdoctoral", 
            "phone": "82-53-250-8015"
        }, 
        "overall_official": {
            "affiliation": "Keimyung University Dongsan Medical Center", 
            "last_name": "Chang-Wook Nam, Postdoctoral", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "All cause death, non fatal myocardial infarction, any revascularization", 
            "measure": "2-year composite end points", 
            "safety_issue": "Yes", 
            "time_frame": "up to 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01947439"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Keimyung University Dongsan Medical Center", 
            "investigator_full_name": "NAM, Chang-Wook", 
            "investigator_title": "Associate Professor of Internal Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "All cause death", 
                "safety_issue": "Yes", 
                "time_frame": "up to 2 years"
            }, 
            {
                "measure": "non-cardiac death", 
                "safety_issue": "Yes", 
                "time_frame": "up to 2 years"
            }, 
            {
                "measure": "cardiac death", 
                "safety_issue": "Yes", 
                "time_frame": "up to 2 years"
            }, 
            {
                "measure": "non fatal myocardial infarction", 
                "safety_issue": "Yes", 
                "time_frame": "up to 2 years"
            }, 
            {
                "measure": "Any revascularization", 
                "safety_issue": "Yes", 
                "time_frame": "up to 2 years"
            }, 
            {
                "measure": "Target lesion revascularization", 
                "safety_issue": "Yes", 
                "time_frame": "up to 2 years"
            }, 
            {
                "measure": "Target vessel revascularization", 
                "safety_issue": "Yes", 
                "time_frame": "up to 2 years"
            }, 
            {
                "measure": "stent thrombosis", 
                "safety_issue": "Yes", 
                "time_frame": "up to 2 years"
            }
        ], 
        "source": "Keimyung University Dongsan Medical Center", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Dio", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Medtronic", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Keimyung University Dongsan Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}